O'Reilly R A
Clin Pharmacol Ther. 1980 Feb;27(2):198-201. doi: 10.1038/clpt.1980.31.
Spironolactone has been reported to diminish the hypoprothrombinemic effect of oral anticoagulants in animals and digitoxin blood levels in man by induction of hepatic enzymes. To evaluate this in man, single oral doses of racemic warfarin, 1.5 mg/kg body weight, with and without 200 mg oral spironolactine daily, were administered to 9 normal subjects. Daily venous blood samples were analyzed for 1-stage prothrombin activity, hematocrit, and warfarin content. There was a decrease in hypoprothrombinemic effect (p less than 0.01), an increase in venous hematocrit (p less than 0.001), and no change in warfarin level (p greater than 0.5) during warfarin with spironolactone-induced diuresis over that with warfarin alone. It is concluded that the interaction of warfarin and spironolactone results primarily from the diuresis with consequent concentration of clotting factors and decreased anticoagulant effect.
据报道,螺内酯可通过诱导肝酶,降低动物口服抗凝剂的低凝血酶原血症效应以及人体中的洋地黄毒苷血药浓度。为了在人体中评估这一情况,对9名正常受试者分别给予单剂量口服消旋华法林(1.5 mg/kg体重),其中部分受试者每日加服200 mg口服螺内酯。每日采集静脉血样,分析一期凝血酶原活性、血细胞比容和华法林含量。与单独使用华法林相比,在螺内酯诱导利尿的华法林治疗期间,低凝血酶原血症效应降低(p<0.01),静脉血细胞比容升高(p<0.001),而华法林水平无变化(p>0.5)。结论是,华法林与螺内酯的相互作用主要源于利尿作用,从而导致凝血因子浓度升高和抗凝作用减弱。